Edwards Lifesciences Corporation $EW Shares Acquired by Fulcrum Capital LLC

Fulcrum Capital LLC grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 3.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 131,109 shares of the medical research company’s stock after purchasing an additional 4,842 shares during the quarter. Edwards Lifesciences makes up approximately 2.2% of Fulcrum Capital LLC’s portfolio, making the stock its 16th largest holding. Fulcrum Capital LLC’s holdings in Edwards Lifesciences were worth $10,254,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of EW. Allspring Global Investments Holdings LLC lifted its stake in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after buying an additional 145 shares during the period. Pacific Capital Partners Ltd purchased a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $1,760,000. Czech National Bank lifted its stake in shares of Edwards Lifesciences by 5.8% during the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after buying an additional 7,917 shares during the period. Dynamic Advisor Solutions LLC lifted its stake in shares of Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company’s stock valued at $1,124,000 after buying an additional 370 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in shares of Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock valued at $5,582,000 after buying an additional 9,188 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EW. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Stifel Nicolaus set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Monday, September 22nd. Barclays increased their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Finally, BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $87.06.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $74.02 on Friday. The company’s fifty day simple moving average is $78.09 and its 200-day simple moving average is $76.10. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company has a market cap of $43.46 billion, a PE ratio of 10.65, a P/E/G ratio of 3.61 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $0.70 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.